Product Images Lacosamide

This is a medication description for NDC 42291-860-60 containing 50 mg of lacosamide, with dosage information available in the package insert. The tablets should be stored between 20-25°C (68-77°F) with excursions up to 25°C (86°F). The medication guide should be provided to each patient receiving the Rx. The tablets are manufactured by Amneal Pharmaceuticals and the label includes the manufacturer's address.*

NDC 42291-861-60 is a medication guide for Lacosamide tablets, USP, produced by Akare. Each film-coated tablet contains 100mg of lacosamide. It is advised to keep the tablets at a temperature of 20 to 25°C. The dosage information can be found in the package insert. Children should not have access to this medication. It is manufactured by Amneal Pharmaceutical of New York, LLC in Brookhaven.*

NDC 42291-862-60 is a medication called Lacosamide manufactured by AVKARE. It is a film-coated tablet that contains 150 mg of lacosamide, USP. The package insert contains dosage information. The medication should be stored at 20" to 25°C (66" to 77°F); excursions permitted between 1510 30°C (59" to 86'F) [see USP Controlled Room Temperature]. The medication is manufactured by Amneal Pharmaceuticals of New York, LLC, Brookhaven, NY 11719. The label warns to keep it out of the reach of children. There is also a non-varnished area for lot number, expiration date, and serialization.*

This is a medication information for Lacosamide, USP tablets. Each film-coated tablet contains 200mg of lacosamide. It comes in a bottle of 60 tablets and the recommended dosage is indicated in the package insert. The medication guide must be dispensed with each prescription, and the medication should be stored at the recommended temperature. It has been manufactured by Amneal Pharmaceuticals of New York, LLC and distributed by Avkare. The manufacturing and expiration date, lot number, and serialization are not available.*

The text describes a figure (Figure 1) showing the percentage reduction in seizure frequency per 28 days during the Maintenance Phase by Dose. The data is presented for various medications, including Lacosamide and Placebo, at different mg/day doses. The figure indicates a statistically significant difference in seizure reduction in some of the treatments compared to Placebo.*

This is a graph labeled as "Figure 2" showing the proportion of patients by Responder Rate for the Lacosamide and Placebo groups in Studies 2, 3, and 4. The Responder Rate is expressed as a percentage on the y-axis, ranging from 0% to 100%. The x-axis shows the different levels of Responder Rate in increments of 10%. The graph displays three groups: Placebo (composed of 359 participants), Lacosamide 400mg/day (composed of 466 participants), and Lacosamide 600mg/day (composed of 202 participants).*